Exploring 3 High Growth Tech Stocks in the US Market

As of November 6, 2025, the United States market has been experiencing volatility with major stock indexes like the Nasdaq and S&P 500 closing lower due to resurfacing concerns about AI valuations and a significant uptick in job cuts reported for October. In this environment of fluctuating economic indicators and heightened scrutiny on tech valuations, identifying high growth tech stocks involves looking at companies that demonstrate resilience through innovation and adaptability in their business strategies.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating Exelixis 11.26% 21.94% ★★★★★☆ Palantir Technologies 26.74% 29.17% ★★★★★★ Workday 11.19% 32.07% ★★★★★☆ Praxis Precision Medicines 74.33% 58.23% ★★★★★★ RenovoRx 65.52% 68.63% ★★★★★☆ Circle Internet Group 27.53% 82.41% ★★★★★☆ OS Therapies 56.64% 68.61% ★★★★★☆ Gorilla Technology Group 32.75% 122.61% ★★★★★☆ Procore Technologies 12.13% 86.69% ★★★★★☆ Zscaler 15.72% 40.94% ★★★★★☆

Click here to see the full list of 74 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

MiMedx Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: MiMedx Group, Inc. specializes in developing and distributing placental tissue allografts for diverse healthcare sectors, with a market capitalization of approximately $1.18 billion.

Operations: The company generates revenue primarily from the biotechnology sector, specifically focusing on startups, with a revenue of $393.44 million.

MiMedx Group, a player in the biotech sector, recently uplifted its earnings guidance for 2025, anticipating mid-to-high teen percentage growth in net sales year-over-year. This revision follows a robust third quarter where revenues surged to $113.73 million from $84.06 million, and net income doubled to $16.75 million from the previous year's $8.1 million. Additionally, the launch of EPIXPRESS®, enhancing their wound care portfolio, aligns with industry shifts towards specialized treatments for chronic conditions like diabetic foot ulcers, potentially boosting future revenue streams amidst a competitive landscape where innovation is key to growth.

Take a closer look at MiMedx Group's potential here in our health report. Evaluate MiMedx Group's historical performance by accessing our past performance report.MDXG Revenue and Expenses Breakdown as at Nov 2025

Red Violet

Simply Wall St Growth Rating: ★★☆☆☆☆

Overview: Red Violet, Inc. is an analytics and information solutions company that focuses on using proprietary technologies and analytical capabilities to provide identity intelligence in the United States, with a market cap of $762.21 million.

Lire la suite

Operations: The company leverages proprietary technologies to offer identity intelligence solutions within the U.S. Its operations are centered on analytics and information solutions, contributing to a market cap of $762.21 million.

Red Violet's recent performance underscores its potential in the tech sector, with a notable 120.9% earnings growth outpacing the software industry's average of 18.4%. This surge is mirrored by a steady revenue increase to $23.08 million in Q3 2025, up from $19.06 million the previous year, reflecting an annual growth rate of 13.4%. The company also demonstrated strategic financial management through a share repurchase initiative, buying back shares worth $11.08 million since May 2022 and boosting shareholder value by increasing buyback authorization to $30 million recently. These moves highlight Red Violet’s robust operational execution and responsiveness to market dynamics, positioning it as a resilient contender amidst tech innovators.

Click here to discover the nuances of Red Violet with our detailed analytical health report. Gain insights into Red Violet's past trends and performance with our Past report.RDVT Earnings and Revenue Growth as at Nov 2025

Praxis Precision Medicines

Simply Wall St Growth Rating: ★★★★★★

Overview: Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, with a market cap of $4.12 billion.

Operations: Praxis Precision Medicines focuses on developing therapies targeting central nervous system disorders with a market cap of approximately $4.12 billion. As a clinical-stage company, it primarily invests in research and development to advance its therapeutic candidates, without generating revenue from product sales yet.

Praxis Precision Medicines, amidst a challenging financial landscape marked by a net loss of $73.93 million in Q3 2025, continues to push forward with significant R&D efforts. The company's alignment with the FDA on its relutrigine program highlights its strategic focus on developing treatments for rare pediatric epilepsies, underpinning its potential to address unmet medical needs. Recent follow-on equity offerings totaling over $775 million underscore investor confidence and provide crucial funding to advance Praxis's innovative pipeline, including promising Phase 3 results in essential tremor studies which reflect meaningful improvements in patient outcomes.

Click to explore a detailed breakdown of our findings in Praxis Precision Medicines' health report. Gain insights into Praxis Precision Medicines' historical performance by reviewing our past performance report.PRAX Revenue and Expenses Breakdown as at Nov 2025

Where To Now?

Dive into all 74 of the US High Growth Tech and AI Stocks we have identified here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Contemplating Other Strategies?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MDXGRDVT and PRAX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Afficher les commentaires